Search

Author/Creator Maruyama, Hirotaka

1. Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT). (December 2021)

Authors:
Sakata, Yoshihiko; Sakata, Shinya; Oya, Yuko; Tamiya, Motohiro; Suzuki, Hidekazu; Shibaki, Ryota; Okada, Asuka; Kobe, Hiroshi; Matsumoto, Hirotaka; Yokoi, Takashi; Sato, Yuki; Uenami, Takeshi; Saito, Go; Tsukita, Yoko; Inaba, Megumi; Ikeda, Hideki; Arai, Daisuke; Maruyama, Hirotaka; Hara, Satoshi...
Journal:
European journal of cancer
Issue:
Volume 159(2021)
Page Start:
144
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study. (January 2023)

Authors:
Imaji, Mihoko; Fujimoto, Daichi; Sato, Yuki; Sakata, Yoshihiko; Oya, Yuko; Tamiya, Motohiro; Suzuki, Hidekazu; Ikeda, Hideki; Kijima, Takashi; Matsumoto, Hirotaka; Kanazu, Masaki; Hino, Aoi; Inaba, Megumi; Tsukita, Yoko; Arai, Daisuke; Maruyama, Hirotaka; Hara, Satoshi; Tsumura, Shinsuke; Kobe, H...
Journal:
European journal of cancer
Issue:
Volume 179(2023)
Page Start:
15
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search